Go Pro

Craneware (CRW) Competitors

Craneware logo
GBX 1,114 +16.00 (+1.46%)
As of 12:32 PM Eastern

CRW vs. EMIS, INS, KOO, COG, and INHC

Should you buy Craneware stock or one of its competitors? MarketBeat compares Craneware with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Craneware include EMIS Group (EMIS), Instem (INS), Kooth (KOO), Cambridge Cognition (COG), and Induction Healthcare Group (INHC). These companies are all part of the "health information services" industry.

How does Craneware compare to EMIS Group?

Craneware (LON:CRW) and EMIS Group (LON:EMIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

EMIS Group has lower revenue, but higher earnings than Craneware. EMIS Group is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£211.33M1.80£14.27M£62.9017.71
EMIS Group£176.86M0.00£30.48M£0.47N/A

36.4% of Craneware shares are held by institutional investors. Comparatively, 105.6% of EMIS Group shares are held by institutional investors. 10.3% of Craneware shares are held by insiders. Comparatively, 3.6% of EMIS Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Craneware has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market. Comparatively, EMIS Group has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

EMIS Group has a net margin of 17.23% compared to Craneware's net margin of 10.63%. EMIS Group's return on equity of 23.17% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware10.63% 6.65% 2.28%
EMIS Group 17.23%23.17%7.99%

In the previous week, Craneware had 7 more articles in the media than EMIS Group. MarketBeat recorded 7 mentions for Craneware and 0 mentions for EMIS Group. Craneware's average media sentiment score of 0.44 beat EMIS Group's score of 0.00 indicating that Craneware is being referred to more favorably in the media.

Company Overall Sentiment
Craneware Neutral
EMIS Group Neutral

Craneware pays an annual dividend of GBX 41.96 per share and has a dividend yield of 3.8%. EMIS Group pays an annual dividend of GBX 42 per share. Craneware pays out 66.7% of its earnings in the form of a dividend. EMIS Group pays out 8,936.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Craneware is clearly the better dividend stock, given its higher yield and lower payout ratio.

Craneware presently has a consensus target price of GBX 2,222.75, suggesting a potential upside of 99.53%. Given Craneware's stronger consensus rating and higher probable upside, research analysts clearly believe Craneware is more favorable than EMIS Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
EMIS Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Craneware beats EMIS Group on 11 of the 17 factors compared between the two stocks.

How does Craneware compare to Instem?

Craneware (LON:CRW) and Instem (LON:INS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Craneware currently has a consensus price target of GBX 2,222.75, suggesting a potential upside of 99.53%. Given Craneware's stronger consensus rating and higher probable upside, equities analysts plainly believe Craneware is more favorable than Instem.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Instem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

36.4% of Craneware shares are held by institutional investors. Comparatively, 65.9% of Instem shares are held by institutional investors. 10.3% of Craneware shares are held by insiders. Comparatively, 30.0% of Instem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Craneware has higher revenue and earnings than Instem. Instem is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£211.33M1.80£14.27M£62.9017.71
Instem£61.63M0.00£3.34M£0.14N/A

Craneware has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Instem has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

In the previous week, Craneware had 7 more articles in the media than Instem. MarketBeat recorded 7 mentions for Craneware and 0 mentions for Instem. Craneware's average media sentiment score of 0.44 beat Instem's score of 0.00 indicating that Craneware is being referred to more favorably in the media.

Company Overall Sentiment
Craneware Neutral
Instem Neutral

Craneware has a net margin of 10.63% compared to Instem's net margin of 5.50%. Craneware's return on equity of 6.65% beat Instem's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware10.63% 6.65% 2.28%
Instem 5.50%6.35%4.62%

Summary

Craneware beats Instem on 10 of the 15 factors compared between the two stocks.

How does Craneware compare to Kooth?

Kooth (LON:KOO) and Craneware (LON:CRW) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

Kooth presently has a consensus target price of GBX 330, suggesting a potential upside of 98.56%. Craneware has a consensus target price of GBX 2,222.75, suggesting a potential upside of 99.53%. Given Craneware's higher possible upside, analysts clearly believe Craneware is more favorable than Kooth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Craneware had 7 more articles in the media than Kooth. MarketBeat recorded 7 mentions for Craneware and 0 mentions for Kooth. Craneware's average media sentiment score of 0.44 beat Kooth's score of 0.00 indicating that Craneware is being referred to more favorably in the news media.

Company Overall Sentiment
Kooth Neutral
Craneware Neutral

Craneware has a net margin of 10.63% compared to Kooth's net margin of 4.12%. Kooth's return on equity of 8.84% beat Craneware's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth4.12% 8.84% 10.12%
Craneware 10.63%6.65%2.28%

Craneware has higher revenue and earnings than Kooth. Craneware is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£63.29M0.95£4.00M£7.0023.74
Craneware£211.33M1.80£14.27M£62.9017.71

Kooth has a beta of 1.299, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Craneware has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

21.0% of Kooth shares are held by institutional investors. Comparatively, 36.4% of Craneware shares are held by institutional investors. 30.4% of Kooth shares are held by insiders. Comparatively, 10.3% of Craneware shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Craneware beats Kooth on 10 of the 15 factors compared between the two stocks.

How does Craneware compare to Cambridge Cognition?

Cambridge Cognition (LON:COG) and Craneware (LON:CRW) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, Craneware had 6 more articles in the media than Cambridge Cognition. MarketBeat recorded 7 mentions for Craneware and 1 mentions for Cambridge Cognition. Cambridge Cognition's average media sentiment score of 0.67 beat Craneware's score of 0.44 indicating that Cambridge Cognition is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cambridge Cognition
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Craneware
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

15.9% of Cambridge Cognition shares are owned by institutional investors. Comparatively, 36.4% of Craneware shares are owned by institutional investors. 3.3% of Cambridge Cognition shares are owned by insiders. Comparatively, 10.3% of Craneware shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cambridge Cognition currently has a consensus price target of GBX 56, indicating a potential upside of 63.50%. Craneware has a consensus price target of GBX 2,222.75, indicating a potential upside of 99.53%. Given Craneware's higher possible upside, analysts clearly believe Craneware is more favorable than Cambridge Cognition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cambridge Cognition
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Craneware has a net margin of 10.63% compared to Cambridge Cognition's net margin of -17.82%. Craneware's return on equity of 6.65% beat Cambridge Cognition's return on equity.

Company Net Margins Return on Equity Return on Assets
Cambridge Cognition-17.82% -62.89% -0.30%
Craneware 10.63%6.65%2.28%

Craneware has higher revenue and earnings than Cambridge Cognition. Cambridge Cognition is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cambridge Cognition£9.40M1.70-£1.58M-£3.90N/A
Craneware£211.33M1.80£14.27M£62.9017.71

Cambridge Cognition has a beta of 0.804, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Craneware has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Summary

Craneware beats Cambridge Cognition on 13 of the 15 factors compared between the two stocks.

How does Craneware compare to Induction Healthcare Group?

Craneware (LON:CRW) and Induction Healthcare Group (LON:INHC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

Craneware presently has a consensus target price of GBX 2,222.75, suggesting a potential upside of 99.53%. Given Craneware's stronger consensus rating and higher probable upside, research analysts clearly believe Craneware is more favorable than Induction Healthcare Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Craneware
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Induction Healthcare Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Craneware has a net margin of 10.63% compared to Induction Healthcare Group's net margin of -23.86%. Craneware's return on equity of 6.65% beat Induction Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Craneware10.63% 6.65% 2.28%
Induction Healthcare Group -23.86%-14.58%-7.32%

Craneware has higher revenue and earnings than Induction Healthcare Group. Induction Healthcare Group is trading at a lower price-to-earnings ratio than Craneware, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Craneware£211.33M1.80£14.27M£62.9017.71
Induction Healthcare Group£12.57M0.72-£5.12M-£5.54N/A

Craneware has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, Induction Healthcare Group has a beta of -0.41, suggesting that its stock price is 141% less volatile than the broader market.

In the previous week, Craneware had 7 more articles in the media than Induction Healthcare Group. MarketBeat recorded 7 mentions for Craneware and 0 mentions for Induction Healthcare Group. Craneware's average media sentiment score of 0.44 beat Induction Healthcare Group's score of 0.00 indicating that Craneware is being referred to more favorably in the media.

Company Overall Sentiment
Craneware Neutral
Induction Healthcare Group Neutral

36.4% of Craneware shares are owned by institutional investors. Comparatively, 46.3% of Induction Healthcare Group shares are owned by institutional investors. 10.3% of Craneware shares are owned by insiders. Comparatively, 54.6% of Induction Healthcare Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Craneware beats Induction Healthcare Group on 14 of the 16 factors compared between the two stocks.

Get Craneware News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRW vs. The Competition

MetricCranewareHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£381.40M£311.15M£6.92B£2.83B
Dividend Yield3.10%5.67%2.66%6.15%
P/E Ratio17.71295.7627.35369.23
Price / Sales1.80137.79503.2986,098.39
Price / Cash14.7247.1429.6527.87
Price / Book1.197.6211.067.84
Net Income£14.27M-£22.78M£3.57B£5.89B
7 Day Performance-18.27%0.38%2.56%0.86%
1 Month Performance-26.13%1.39%7.39%-0.47%
1 Year Performance-50.27%-9.19%34.13%70.60%

Craneware Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CRW
Craneware
4.4154 of 5 stars
GBX 1,114
+1.5%
GBX 2,222.75
+99.5%
-51.0%£381.40M£211.33M17.71734
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560
INS
Instem
N/AN/AN/AN/A£199.62M£61.63M5,928.57500
KOO
Kooth
N/AGBX 159.75
+1.1%
GBX 330
+106.6%
-16.6%£57.94M£63.29M22.82478
COG
Cambridge Cognition
1.9476 of 5 stars
GBX 34.30
+3.9%
GBX 56
+63.3%
+6.8%£15.97M£9.40MN/A80

Related Companies and Tools


This page (LON:CRW) was last updated on 7/6/2026 by MarketBeat.com Staff.
From Our Partners